Blood test to track immunotherapy response in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage 4 or inoperable stage 3B lung cancer (non-small cell type).
- You are about to start or are already receiving a type of immunotherapy called an anti-PD-1 or anti-PD-L1 antibody (like Keytruda, Tecentriq, or Imfinzi).
- You are not getting radiation therapy as your main treatment for lung cancer.
- You do not have small-cell lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This study looks for blood markers that can predict how well certain lung cancer treatments work before surgery. By joining, you help find a simple blood test to guide personalized care.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.